Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Oncology

Genetics and Biomarkers: BRCA, HOXB13, and Beyond

At a Glance

Inherited genetic mutations, such as BRCA2 and HOXB13, play a major role in how prostate cancer develops and behaves. Multigene germline testing is now a standard tool to help identify targeted treatment options like PARP inhibitors and to alert family members to their own cancer risks.

For many years, prostate cancer was treated as a single disease. We now know it is a collection of different diseases driven by unique genetic “blueprints.” Understanding your specific genetic makeup—through germline testing (testing the DNA you were born with)—can explain why the cancer developed, how it might behave, and which treatments are most likely to work [1][2].

The “Repair Crew”: DNA Damage Repair (DDR)

To understand why certain mutations are dangerous, it helps to think of your DNA as a massive library of instructions. Every day, these instructions get slightly damaged. Your cells have a specialized “repair crew” of proteins that fix these errors.

The most important repair process for prostate cancer is Homologous Recombination Repair (HRR). Think of HRR as a precision repair team that uses a backup copy of the DNA to perfectly fix broken strands.

  • The Defect: When genes like BRCA1, BRCA2, or ATM are mutated, the precision repair team is “on strike” [3][4].
  • The Consequence: Without this repair crew, the cell accumulates more and more DNA errors. These errors eventually lead to genomic instability, allowing the cell to grow uncontrollably and form an aggressive, fast-moving tumor [3][5].

Key Genetic Players

Several specific genes have been identified as major contributors to hereditary prostate cancer risk.

BRCA2 and BRCA1

While often associated with breast and ovarian cancer, BRCA2 is the most significant genetic risk factor for aggressive prostate cancer [6].

  • Impact: Men with BRCA2 mutations often develop cancer at a younger age and are more likely to have “high-grade” tumors that spread to other organs [6][7].
  • BRCA1: This gene also increases risk, though generally less significantly than BRCA2 [8].

HOXB13 (The G84E Mutation)

Unlike the repair genes, HOXB13 is involved in the development of the prostate itself.

  • Early Onset: The specific G84E variant is a “red flag” for early-onset disease, often appearing in men in their 40s or 50s [9][10].
  • Risk Profile: While it strongly increases the chance of getting cancer, some studies suggest the cancer it causes may not always be more aggressive than average [10][11].

ATM and CHEK2

These genes act as the “scouts” of the repair crew, signaling when DNA damage has occurred. Mutations in ATM are linked to a fourfold increase in risk and are often found in earlier-onset or advanced cases [12][8].

Lynch Syndrome (Mismatch Repair)

Lynch Syndrome is caused by mutations in genes like MSH2, MSH6, MLH1, and PMS2. These genes fix “typos” in DNA. If they are broken, the tumor may have a very high number of mutations, making it potentially more visible to the immune system and responsive to immunotherapy [13][14].

Why Multigene Panel Testing is Standard

In the past, doctors might only test for one or two genes. Today, the standard of care is a multigene germline panel [2].

  1. Actionable Information: Knowing you have an HRR defect (like BRCA2) can make you eligible for specific drugs called PARP inhibitors, which trap the remaining repair tools and “starve” the cancer cells of their ability to survive [3][15].
  2. Comprehensive Screening: Because many different mutations can cause similar-looking cancers, a single panel test ensures nothing is missed [16].
  3. Family Protection: Your results serve as a “genetic early warning system” for your relatives, allowing them to start screening earlier and potentially catch cancer in its most treatable stages [1][17].

Current guidelines now recommend germline testing for all men with metastatic prostate cancer, regardless of their family history, and increasingly for men with high-risk localized disease [18][19].

Common questions in this guide

Who should get genetic testing for prostate cancer?
Current guidelines recommend germline testing for all men with metastatic prostate cancer, regardless of their family history. It is also increasingly recommended for men with high-risk localized disease to help doctors make more informed treatment decisions.
What does a BRCA2 mutation mean for my prostate cancer diagnosis?
A BRCA2 mutation is a significant genetic risk factor that often leads to more aggressive, high-grade prostate tumors at a younger age. However, having this mutation may also make you eligible for highly effective targeted treatments called PARP inhibitors.
How does the HOXB13 gene affect prostate cancer risk?
The HOXB13 gene, specifically the G84E variant, is strongly linked to early-onset prostate cancer, often appearing in men in their 40s or 50s. While it increases the likelihood of developing the disease, it does not automatically mean the cancer will be highly aggressive.
What is a multigene germline panel test?
A multigene germline panel is a single test that screens your inherited DNA for multiple genetic mutations linked to cancer. This comprehensive test ensures no critical mutations are missed and helps doctors tailor a specific treatment plan for your cancer.
How do my genetic test results affect my family?
Your genetic results act as an early warning system for your blood relatives. If you have an inherited mutation like BRCA2 or HOXB13, your children and siblings can undergo screening to catch potential cancers in their earliest, most treatable stages.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my diagnosis, am I a candidate for a multigene germline panel test, and which specific genes will be screened?
  2. 2.How do my specific genetic results (e.g., BRCA2 or ATM mutation) change my eligibility for targeted therapies if my cancer ever progresses?
  3. 3.Does my genetic profile suggest that my cancer is more likely to be aggressive or spread to other parts of my body?
  4. 4.If a mutation is found, what specific screening or prevention recommendations should I share with my children and siblings?
  5. 5.What resources or genetic counselors do you recommend to help me communicate these risks to my family members?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.

    Shore N, Nielsen SM, Esplin ED, et al.

    JCO oncology practice 2025; (21(6)):747-753 doi:10.1200/OP-24-00626.

    PMID: 39700441
  2. 2

    Diagnosing hereditary cancer predisposition in men with prostate cancer.

    Pritzlaff M, Tian Y, Reineke P, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2020; (22(9)):1517-1523 doi:10.1038/s41436-020-0830-5.

    PMID: 32439974
  3. 3

    PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures.

    McNevin CS, Cadoo K, Baird AM, et al.

    Cancers 2022; (14(19)) doi:10.3390/cancers14194751.

    PMID: 36230674
  4. 4

    Impact of DNA damage repair alterations on prostate cancer progression and metastasis.

    Lukashchuk N, Barnicle A, Adelman CA, et al.

    Frontiers in oncology 2023; (13()):1162644 doi:10.3389/fonc.2023.1162644.

    PMID: 37434977
  5. 5

    Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.

    Wei Y, Wu J, Gu W, et al.

    The oncologist 2020; (25(7)):e1042-e1050 doi:10.1634/theoncologist.2019-0495.

    PMID: 32190957
  6. 6

    Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.

    Nyberg T, Frost D, Barrowdale D, et al.

    European urology 2020; (77(1)):24-35 doi:10.1016/j.eururo.2019.08.025.

    PMID: 31495749
  7. 7

    Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer.

    Boyle JL, Hahn AW, Kapron AL, et al.

    JCO precision oncology 2020; (4()) doi:10.1200/PO.19.00284.

    PMID: 32923906
  8. 8

    Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.

    Na R, Zheng SL, Han M, et al.

    European urology 2017; (71(5)):740-747 doi:10.1016/j.eururo.2016.11.033.

    PMID: 27989354
  9. 9

    Inherited Predisposition to Prostate Cancer: From Gene Discovery to Clinical Impact.

    Cooney KA

    Transactions of the American Clinical and Climatological Association 2017; (128()):14-23.

    PMID: 28790484
  10. 10

    Association of HOXB13 G84E With Prostate Cancer Among 592,158 Men.

    Crawford TB, Nelson T, Karunamuni R, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2025; (23(10)).

    PMID: 40953603
  11. 11

    Association between germline homeobox B13 (HOXB13) G84E allele and prostate cancer susceptibility: a meta-analysis and trial sequential analysis.

    Zhang J, Xiao L, Qin Z, et al.

    Oncotarget 2016; (7(41)):67101-67110 doi:10.18632/oncotarget.11937.

    PMID: 27626483
  12. 12

    Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study.

    Karlsson Q, Brook MN, Dadaev T, et al.

    European urology oncology 2021; (4(4)):570-579 doi:10.1016/j.euo.2020.12.001.

    PMID: 33436325
  13. 13

    PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study.

    Du XX, Dong YH, Zhu HJ, et al.

    Asian journal of andrology 2023; (25(2)):179-183 doi:10.4103/aja2022102.

    PMID: 36537376
  14. 14

    Diverse immune response of DNA damage repair-deficient tumors.

    Qing T, Jun T, Lindblad KE, et al.

    Cell reports. Medicine 2021; (2(5)):100276 doi:10.1016/j.xcrm.2021.100276.

    PMID: 34095878
  15. 15

    The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer.

    Teppala S, Scuffham PA, Tuffaha H

    International journal of technology assessment in health care 2024; (40(1)):e14 doi:10.1017/S0266462324000011.

    PMID: 38439629
  16. 16

    Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.

    Desmond A, Kurian AW, Gabree M, et al.

    JAMA oncology 2015; (1(7)):943-51 doi:10.1001/jamaoncol.2015.2690.

    PMID: 26270727
  17. 17

    Genetically Informed Prostate Cancer Screening.

    Arcot R, Morgan TM, Polascik TJ

    The Urologic clinics of North America 2021; (48(3)):373-386 doi:10.1016/j.ucl.2021.04.001.

    PMID: 34210492
  18. 18

    Guidelines for genetic testing in prostate cancer: a scoping review.

    Tuffaha H, Edmunds K, Fairbairn D, et al.

    Prostate cancer and prostatic diseases 2024; (27(4)):594-603 doi:10.1038/s41391-023-00676-0.

    PMID: 37202470
  19. 19

    Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome.

    Yadav S, Hart SN, Hu C, et al.

    JCO precision oncology 2019; (3()) doi:10.1200/PO.19.00067.

    PMID: 32923857

This page provides educational information about prostate cancer genetics and biomarker testing. Always consult your oncologist or a genetic counselor to understand what your specific genetic results mean for your treatment and family.

Get notified when new evidence is published on Familial prostate carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.